Dyax Corp. (NASDAQ: DYAX) today announced dosing of the first subject in a Phase 1 clinical study evaluating the safety and tolerability of single subcutaneous administration of DX-2930, its fully human monoclonal antibody inhibitor of plasma kallikrein. Dyax, a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma kallikrein-mediated disorders, is developing DX-2930 as a subcutaneous injection for prevention of HAE attacks. DX-2930 was discovered using Dyax’s proprietary phage display technology platform.
“There is significant need for a highly effective, safe and well tolerated prophylactic agent to treat HAE,” said Burt Adelman M.D., Executive Vice President and Chief Medical Officer at Dyax. “DX-2930 is a highly potent, long-acting, fully human monoclonal antibody that binds specifically to active plasma kallikrein. We look forward to completing this study and moving forward rapidly with this important clinical program.”
This Phase 1, single-center, randomized, double-blind, placebo-controlled study is designed to assess the safety and tolerability and to characterize the pharmacokinetics (PK) of single, subcutaneous administrations of DX-2930 in healthy subjects. Approximately 32 subjects will be enrolled into four ascending dose cohorts (n=8 per cohort) of DX-2930 or placebo. The study will be conducted at the clinical trials unit of Vince & Associates Clinical Research, a recognized “Center of Research Excellence”, located in Overland Park, Kansas.
“The successful dosing of the first subject in this Phase 1 clinical study is an important milestone for the DX-2930 development program,” said Gustav Christensen, President and CEO of Dyax. “We believe our knowledge of the plasma kallikrein pathway provides us with unique insight and a significant advantage in developing and commercializing this product candidate.”About DX-2930 Discovered using Dyax’s proprietary phage display technology platform, DX-2930 is a novel, fully human monoclonal antibody inhibitor of plasma kallikrein. Uncontrolled plasma kallikrein activity leads to excessive generation of bradykinin, a vasodilator thought to be responsible for the localized swelling, inflammation and pain characteristically associated with HAE. Preclinical studies suggest that DX-2930 will have a long half-life in humans, offering the potential for a long-acting and sustained therapeutic effect with less frequent dosing. Dyax is currently developing DX-2930 as a subcutaneous injection for the prevention of HAE attacks.